Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.
Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).
Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.
Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 14, 2020
Time: 08:02 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/4772jrtc
52-week high: $6.00
52-week low: $0.71
Price action over last quarter: Up 27.07%
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.